Skip to main content

JOHNSON & JOHNSON

For the period ended Apr 25, 2024. Filed Mar 13, 2024.

View on SEC.gov

About this filing

What shareholders are asked to vote on at a company's meeting. It is where to find what directors and top executives are paid, and who owns the most shares.

Apr 25, 2024 · Filed Mar 13, 2024

JNJ$276.22+1.4%Stored close · as of Nov 6, 2026
See the whole filing, with its images and exhibits
Contents

Cover page

Show cover page

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Filed by the Registrantý

Filed by a Party other than the Registranto

Check the appropriate box:

oPreliminary Proxy Statement
oConfidential, for the Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
ýDefinitive Proxy Statement
oDefinitive Additional Materials
oSoliciting Material under § 240.14a-12

Johnson & Johnson

(Name of Registrant as Specified in Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than Registrant)

Payment of Filing Fee (Check all boxes that apply):

ýNo fee required.
oFee paid previously with preliminary materials.
oFee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-(6)(i)(4) and 0-11.

March 13, 2024

Notice of Annual Meeting & Proxy Statement

TimeThursday, April 25, 202410:00 a.m., Eastern TimeVotingYou are eligible to vote if you were a shareholder of record at the close of business on February 27, 2024. Ensure that your shares are represented at the meeting by voting in one of several ways:To vote via the internet prior to the meeting, go to the website listed on your proxy card or notice.
To vote by phone, call the telephone number specified on your proxy card or on the website listed on your notice.
If you received paper copies of your proxy materials, mark, sign, date and return your proxy card in the postage-paid envelope provided to vote by mail.
Whether or not you plan to attend the Annual Meeting, we call on you to vote and submit your proxy in advance of the meeting by using one of the methods described above.
Items of businessYou are invited to attend the Annual Meeting of Shareholders of Johnson & Johnson.The 2024 Annual Meeting will be held online in a virtual format.You or your proxyholder will be able to attend the 2024 Annual Meeting online, vote and submit questions by visiting www.virtualshareholdermeeting.com/JNJ2024 and using the 16-digit control number included on your notice, on your proxy card or in the voting instructions that accompanied your proxy materials.
1Elect the 13 nominees named in this Proxy Statement to serve as Directors for the coming year.
2Vote, on an advisory basis, to approve named executive officer compensation.
3Ratify the appointment of PricewaterhouseCoopers LLP as our independent registered public accounting firm for 2024.
4-5Vote on the two shareholder proposals contained in this Proxy Statement, if properly presented at the Annual Meeting.
Transact such other matters as may properly come before the Annual Meeting and at any adjournment or postponement of the Annual Meeting.

By order of the Board of Directors,

Marc Larkins

Worldwide Vice President, Corporate Governance

Corporate Secretary

2024 Proxy Statement1

Important notice regarding the availability of Proxy Materials for the Annual Meeting of Shareholders of Johnson & Johnson

to be held on April 25, 2024.

The Proxy Statement and Annual Report to Shareholders are available at

www.investor.jnj.com/asm

2

Table of contents

5A message from our Lead Director
6Living into Our Credo
82024 Proxy Statement – summary
13Board of Directors and corporate governance
ITEM 1: Election of Directors
132024 Board nominees
14Director nomination process and Board refreshment
16Nominee skills, expertise and background
17Board nominee biographies
24Corporate governance
24Corporate governance highlights
27Board structure and operations
36Oversight of our Company
44Shareholder engagement
46Related person transactions and Director independence
49Director compensation
49Fiscal 2024 non-employee Director compensation
49Fiscal 2023 non-employee Director compensation
51Director compensation policies and practices
51Deferred fee plan for Directors
51Additional arrangements
52Stock ownership guidelines for non-employee Directors
52Stock ownership information
52Security ownership of certain beneficial owners, officers and directors
55Compensation of executives
ITEM 2: Advisory vote to approve named executive officer compensation
56A message from our Compensation & Benefits Committee
57Compensation Committee report
58Compensation discussion and analysis
592023 Executive compensation summary
642023 Executive compensation
71Compensation decisions for 2023 performance
73NEO performance and compensation summaries
77Executive compensation decision process
81Additional information concerning executive compensation
84Compensation policies and practices
85Compensation decisions for 2022 performance
86Reconciliation of non-GAAP performance measures
89Executive compensation tables
89Reconciliation of our CEO's 2023 total direct compensation to the 2023 summary compensation table
922023 Summary compensation table
982023 Grants of plan-based awards
1022023 Outstanding equity awards at fiscal year-end
1052023 Option exercises and stock vested
1052023 Pension benefits
1072023 Non-qualified deferred compensation
1102023 Potential payments upon termination
113Ratio of the annual total compensation of the median-paid employee to the CEO
114Pay versus performance
122Audit matters
122Audit Committee report
ITEM 3: Ratification of appointment of independent registered public accounting firm
124Selection and engagement of audit firm
124Audit and non-audit fees
125Pre-approval of audit and non-audit services
ITEMS 4-5: Shareholder proposals
130Other information
Index of frequently requested information (alphabetical)
131Annual Meeting attendance
85Anti-pledging, hedging policy
124Auditor fees
124Auditor tenure
15Board and Committees evaluation
27Board leadership structure
30Board meeting attendance
113CEO pay ratio
73CEO performance evaluation
78Compensation consultant
59Compensation summary
24Corporate governance highlights
39Cybersecurity
17Director biographies
47Director independence
25Director overboarding policy
14Director qualifications
42Diversity, equity and inclusion
40Environmental, social and governance
85Exec. comp. recoupment policies
41Human capital management
28Lead Director duties and responsibilities
66Long-term incentives
131Notice and access
38Patient safety and product quality
64Pay for performance
79Peer group comparisons
71Perquisites
40Political spending oversight
25Proxy access
46Related person transactions
36Risk oversight
110Severance benefits
44Shareholder engagement
126Shareholder proposals
Stock ownership requirements:
52for non-employee Directors
84for executive officers
130Voting
Websites and resources
135Helpful websites
26Other corporate disclosures
2024 Proxy Statement3

Our Credo

We believe our first responsibility is to the patients, doctors and nurses, to mothers and fathers and all others who use our products and services. In meeting their needs everything we do must be of high quality. We must constantly strive to provide value, reduce our costs and maintain reasonable prices. Customers' orders must be serviced promptly and accurately. Our business partners must have an opportunity to make a fair profit.

We are responsible to our employees who work with us throughout the world. We must provide an inclusive work environment where each person must be considered as an individual. We must respect their diversity and dignity and recognize their merit. They must have a sense of security, fulfillment and purpose in their jobs. Compensation must be fair and adequate and working conditions clean, orderly and safe. We must support the health and well-being of our employees and help them fulfill their family and other personal responsibilities. Employees must feel free to make suggestions and complaints. There must be equal opportunity for employment, development and advancement for those qualified. We must provide highly capable leaders and their actions must be just and ethical.

We are responsible to the communities in which we live and work and to the world community as well. We must help people be healthier by supporting better access and care in more places around the world. We must be good citizens - support good works and charities, better health and education, and bear our fair share of taxes. We must maintain in good order the property we are privileged to use, protecting the environment and natural resources.

Our final responsibility is to our stockholders. Business must make a sound profit. We must experiment with new ideas. Research must be carried on, innovative programs developed, investments made for the future and mistakes paid for. New equipment must be purchased, new facilities provided and new products launched. Reserves must be created to provide for adverse times. When we operate according to these principles, the stockholders should realize a fair return.

4

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.